Berkshire Hathaway Inc.
BRK-B
$575.08
+0.76%
Berkshire Hathaway Inc. is a diversified global conglomerate whose core operations span property/casualty and reinsurance underwriting (Berkshire Hathaway Insurance Group, GEICO, General Re), freight rail (BNSF), regulated utilities and energy infrastructure (BHE), and a sprawling manufacturing, distribution and retail portfolio that includes Precision Castparts, Lubrizol, Clayton Homes, McLane and Pilot Travel Centers. Its competitive identity is unique: a decentralized holding company that functions as a AAA-quality balance-sheet platform, allocating capital across wholly owned operating businesses and a large publicly traded equity portfolio, with a scale and permanence of capital that few institutions can replicate. The current investor narrative centers on the post-Buffett succession era under Greg Abel, the earnings power of a record insurance underwriting cycle, and the redeployment of an enormous cash and Treasury-bill position — the Q2 2026 balance sheet shows roughly $41.4 billion of cash at period end after heavy investment purchases, with continued buyback activity ($4.2 billion repurchased in Q2). Debate is split between bulls who see double-digit revenue growth (Q2 2026 revenue +10.0% YoY to $101.8 billion) and a low-beta, defensive compounder trading near all-time highs, and skeptics who note that a large share of recent net income derives from investment gains and mark-to-market swings rather than core underwriting and operating profit. With no dividend and a stated preference for large acquisitions, the stock's narrative is increasingly a bet on capital deployment discipline and the durability of insurance margins rather than on multiple expansion.…
BRK-B
Berkshire Hathaway Inc.
$575.08
Investment Opinion: Should I buy BRK-B Today?
Rating: Hold (accumulate on weakness). The core thesis is that Berkshire is a high-quality, low-beta compounder (beta 0.571, debt-to-equity 0.194, $24.22 billion TTM free cash flow) whose shares have simply run ahead of published fair value after a 12.77% one-month surge — the average analyst target of $555.67 sits 2.7% below the current $570.95, and the low target of $510.00 implies 10.7% downside, so the risk/reward at spot is balanced rather than compelling. The constructive anchor is that 2 of the 3 covering analysts rate Buy with no Sells, and UBS has reiterated Buy three times in 2026 (2026-07-28, 2026-08-10, 2026-10-22) with no downgrades visible.
Supporting evidence is strong on quality and adequate on price: revenue grew 10.04% YoY to $101.81 billion in Q2 2026, gross margin has held in a tight 23.0–24.6% band for five quarters, and the Q2 2026 EBITDA margin of 20.72% versus 17.55% in Q4 2025 shows operating leverage intact. The balance sheet is unmatched — current ratio 6.75x, interest coverage roughly 13.1x on $1.335 billion of quarterly interest expense against $17.49 billion of operating income — and the stock has beaten SPY by 6.17 points over the year and 20.49 points over six months while taking only 57% of market volatility. Valuation is the weak link: 1.51x price-to-book versus a five-year average near 1.45x (about a 4% premium) and a 25.45x forward PE against 16.21x trailing, with a 23.61x price-to-cash-flow that is rich versus the sector's high-teens norm and a 2.2% FCF yield on the ~$1.09 trillion market cap.
The thesis would upgrade to Buy if the price pulled back toward the $510–$540 zone (the low analyst target and the October breakout area), restoring upside to the $555.67 average target and the $628 high target, or if book value compounding accelerates on a large cash deployment. It would downgrade to Sell if Q3/Q4 underwriting margins compress as the insurance pricing cycle turns while investment gains reverse, pushing the operative multiple toward 25x forward earnings on a shrinking base. Verdict: fairly valued to slightly rich relative to its own history and modestly cheap relative to peers on trailing earnings — a quality holding, not a bargain at $570.95.
Sign up to view all
BRK-B 12-Month Price Forecast
Berkshire's business quality is not in question — 10.04% revenue growth, a 0.194 debt-to-equity ratio, $24.22 billion of TTM free cash flow and a 0.571 beta make it one of the most durable large caps available. The issue is entry price: after a 12.77% one-month gain against SPY's -4.99%, the stock trades above the average analyst target of $555.67 and at a 25.45x forward PE that assumes trailing investment-gain-inflated earnings revert. With only 3 analysts, a consensus recommendation of "none" and a wide $510–$628 target spread, price discovery is thin and the stock is driven more by index flows and buyback cadence than by sell-side revisions. I would upgrade to bullish on a pullback into the $510–$540 zone or on announcement of a large, accretive deployment of the cash pile; I would downgrade to bearish if underwriting margins compress while investment gains reverse, confirming 25.45x as the true multiple.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Berkshire Hathaway Inc.'s 12-month outlook, with a consensus price target around $555.67 and implied upside of -3.4% versus the current price.
Average Target
$555.67
4 analysts
Implied Upside
-3.4%
vs. current price
Analyst Count
4
covering this stock
Price Range
$510 - $628
Analyst target range
Coverage is thin but constructive: only 3 analysts cover BRK-B, with a distribution of 2 Buy, 2 Hold and 0 Sell (the ratings tally sums to 4 against 3 named analysts, indicating overlapping or legacy ratings), and the consensus recommendation field is reported as "none," which itself signals limited formal coverage. The average target price is $555.67, which is actually below the current $570.95 — implying roughly -2.7% downside to consensus — while the low target of $510.00 sits 10.7% below spot and the high target of $628.00 implies +10.0% upside. The consensus therefore leans neutral-to-cautiously-bullish on fundamentals but is, on average, behind the price after the recent 12.8% one-month surge, meaning the stock has run past the Street's published fair values.
The target range of $510–$628 is wide — a 23% spread from low to high — which signals genuine disagreement about the earnings base rather than about the business quality. The high target of $628 likely assumes continued insurance underwriting strength, double-digit book value compounding, accelerated buybacks and successful deployment of the cash pile into a large acquisition, effectively a modest multiple-expansion-plus-book-growth scenario; the low target of $510 likely discounts a normalization of investment gains, softer underwriting margins as the pricing cycle turns, and a higher-for-longer rate environment pressuring the equity portfolio. Institutional ratings show UBS reiterating Buy on 2026-10-22, 2026-08-10 and 2026-07-28 with no downgrades in the visible history, so the directional bias of revisions is positive even as the average target lags the price. The practical implication is that with only 3 analysts, price discovery is less efficient and the stock is more likely to be driven by index flows, buyback cadence and macro risk appetite than by sell-side revisions — and the current -2.7% implied downside to the average target argues for patience rather than chasing the stock at 87.5% of its 52-week range.
Drowning in data?
Find the real signal!
Bulls vs Bears: BRK-B Investment Factors
The bull case currently has the stronger evidence: BRK-B is compounding revenue at 10.04% YoY, carries a 0.194 debt-to-equity ratio, generates $24.22 billion of TTM free cash flow, and has outperformed SPY by 6.17 points over the year with a beta of only 0.571 — a rare combination of quality, growth and low volatility. The bear case is not about business deterioration but about price: the stock trades at 1.51x book (a ~4% premium to its five-year average), a 25.45x forward PE versus 16.21x trailing, and sits 2.7% above the average analyst target of $555.67 after a 12.77% one-month surge. The single most important tension is whether the investment-gain-inflated trailing earnings base is real or whether the forward PE of 25.45x is the truer multiple — if book value compounds at double digits and the $4.2 billion quarterly buyback pace continues, the premium is justified; if investment gains reverse and underwriting margins normalize as the pricing cycle turns, the stock is fairly valued to slightly rich. With only 3 analysts and a wide $510–$628 target range (23% spread), the debate is about the earnings base rather than business quality, and the recent vertical move argues for patience rather than chasing at 87.5% of the 52-week range.
Bullish
- Defensive outperformance with low beta: BRK-B has gained 15.76% over the trailing year versus SPY's 9.59% (+6.17 points of relative strength) while carrying a beta of just 0.571, meaning it delivered that outperformance with roughly 57% of the market's volatility. The 52-week max drawdown of only -14.95% confirms this is a quality/defensive rotation beneficiary rather than a high-beta rally. In a market where SPY is -4.99% over the past month, BRK-B is +12.77%, a +17.76 point relative spread.
- Fortress balance sheet with 0.19 D/E: Debt-to-equity of 0.194, a current ratio of 6.75x and interest coverage of roughly 13.1x (Q2 2026 interest expense of $1.335 billion against $17.49 billion operating income) give Berkshire one of the strongest balance sheets in the S&P 500. This supports the AAA-like credit profile that underpins the insurance float and allows counter-cyclical capital deployment when peers are constrained.
- Revenue compounding at 10% YoY: Q2 2026 revenue reached $101.81 billion, up 10.04% from $92.52 billion in Q2 2025, following $93.68 billion in Q1 2026 versus $89.73 billion a year earlier. The growth is broad-based across Insurance ($26.18 billion), Manufacturing ($22.57 billion), Pilot ($14.93 billion) and McLane ($12.12 billion), giving the conglomerate a diversified, low-cyclicality earnings base.
- Stable gross margins and operating leverage: Gross margin has held in a tight 23.0–24.6% band over the last five quarters (23.37%, 23.06%, 23.01%, 24.62%, 24.12%), while the Q2 2026 EBITDA margin of 20.72% versus 17.55% in Q4 2025 shows operating leverage is intact. TTM free cash flow of $24.22 billion and quarterly FCF of $5.57 billion in Q2 2026 fund both capex ($5.65 billion) and buybacks ($4.21 billion) without leverage.
Bearish
- Price has run past analyst targets: The average analyst target of $555.67 sits 2.7% below the current $570.95, and the low target of $510.00 implies 10.7% downside, meaning the stock has outrun the Street's published fair values after its 12.77% one-month surge. With only 3 analysts covering and a consensus recommendation of "none," price discovery is thin and the stock is more exposed to index flows and buyback cadence than to fundamental re-rating.
- Forward PE of 25.45x signals earnings reversion: The gap between the 16.21x trailing PE and 25.45x forward PE implies the market expects earnings to normalize downward from the investment-gain-inflated trailing base, with consensus 2027 EPS of about $22.91. Upside must therefore come from book value compounding and buybacks rather than multiple expansion, and the trailing multiple flatters the stock.
- Net income driven by mark-to-market swings: Q2 2026 net income of $25.67 billion (25.21% net margin) versus Q1 2026's $10.11 billion (10.79% margin) is explained almost entirely by other income of +$14.57 billion versus -$3.06 billion, confirming that equity portfolio mark-to-market, not underwriting, drives quarter-to-quarter EPS noise. The TTM net margin of 18.03% and operating margin of 15.85% are the cleaner read, and they are materially lower than the headline.
- No dividend and low FCF yield: Payout ratio is 0 and dividend yield is 0%, so total return depends entirely on per-share intrinsic value compounding. The FCF yield is roughly 2.2% on the ~$1.09 trillion market cap and the price-to-free-cash-flow ratio of 23.61x is rich versus the sector's high-teens norm, largely because cash flow is consumed by capex and $172.28 billion of investment purchases in Q2 2026.
BRK-B Technical Analysis
BRK-B is in a sustained, orderly uptrend: the shares are up 15.76% over the trailing year and 14.90% year-to-date, and at $570.95 the price sits at roughly 87.5% of its 52-week range of $464.01–$586.30 — about 2.6% below the high and 23.0% above the low. That positioning signals momentum leadership rather than deep value, but the proximity to the high is not yet an overextension signal given the stock's low beta and the absence of a blow-off volume spike. Notably, the 1-year gain of 15.76% versus SPY's 9.59% implies relative strength of +6.17 percentage points, confirming the trend is one of steady outperformance rather than a high-beta rally. The 52-week maximum drawdown of -14.95% is modest for an equity of this size and underscores the low-volatility character of the move.
Short-term momentum has accelerated sharply and is now diverging positively from the broad market: the stock is +12.77% over the past month versus SPY at -4.99%, a relative strength spread of +17.76 points, and +9.41% over three months against SPY's -4.91% (+14.32 points of relative strength). The 6-month change of +19.95% versus SPY's -0.54% (+20.49 points relative) shows the outperformance is not a one-month anomaly but a persistent rotation into quality/defensive large caps. The recent sequence is telling — the stock jumped from $542.49 on 2026-10-30 to $579.09 on 2026-11-04 before easing to $570.89 on 2026-11-06 — a sharp vertical move that often invites short-term mean reversion, and the most recent session's -0.25% pullback on 5.35 million shares suggests profit-taking at the highs rather than distribution. Because the 1-month gain (+12.77%) is running well ahead of the 1-year pace (+15.76%), the risk is that near-term momentum is borrowing from future returns; a consolidation phase would be healthy rather than trend-breaking.
Key technical levels are well defined: resistance sits at the 52-week high of $586.30, roughly 2.7% above the current $570.95, and a decisive breakout on volume would confirm the uptrend and likely trigger momentum-chasing flows; support rests at the 52-week low of $464.01, some 18.7% below spot, with intermediate support implied by the October breakout zone around $540–$542 where the stock consolidated before its late-October surge. A breakdown below that $540 area would neutralize the bullish structure and put the $500–$510 region (the July/August congestion and the low end of the analyst target range) in play. Volatility is structurally low: beta of 0.571 means the stock has historically moved only about 57% as much as SPY, which argues for larger position sizing per unit of market risk but also means the stock will lag in a sharp risk-on melt-up; the 2.67 short ratio and 5.35 million average volume indicate no meaningful squeeze dynamics, so technical signals here should be read as trend-following rather than event-driven.
Beta
—
—
Max Drawdown
-14.9%
Largest decline past year
52-Week Range
$464-$586
Price range past year
Annual Return
+15.3%
Cumulative gain past year
| Period | BRK-B Return | S&P 500 |
|---|---|---|
| 1m | +11.6% | -3.3% |
| 3m | +11.4% | -2.3% |
| 6m | +18.5% | +1.4% |
| 1y | +15.3% | +12.2% |
| ytd | +15.8% | +10.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BRK-B Fundamental Analysis
Revenue is growing at a solid mid-single-to-low-double-digit pace with visible acceleration: Q2 2026 revenue reached $101.81 billion, up 10.04% year over year from $92.52 billion in Q2 2025, following $93.68 billion in Q1 2026 (versus $89.73 billion a year earlier) and $94.23 billion in Q4 2025. The segment mix shows the growth engines clearly — Manufacturing Businesses at $22.57 billion, Insurance Group at $26.18 billion, Pilot Travel Centers at $14.93 billion, McLane at $12.12 billion, Service & Retailing at $11.88 billion, BHE at $6.74 billion and BNSF at $6.60 billion — with insurance and manufacturing carrying the largest weight and rail/utility providing rate-base and volume-driven stability. The trajectory implies a business compounding revenue at roughly 8–10% with limited cyclicality, which supports the investment case as a defensive compounder, though the growth is partly nominal (insurance pricing, fuel pass-through at Pilot/McLane) rather than purely volume-led.
Profitability is robust but volatile at the net line because of investment gains: Q2 2026 net income was $25.67 billion on a 25.21% net margin, with gross margin of 23.37% and operating margin of 17.18%, while Q1 2026 net income was only $10.11 billion (10.79% net margin) on a 23.06% gross margin and 16.41% operating margin. The swing is explained by other income — Q2 2026 total other income/expense of +$14.57 billion versus -$3.06 billion in Q1 2026 — confirming that mark-to-market on the equity portfolio, not underwriting, drives quarter-to-quarter EPS noise; the trailing twelve-month net margin of 18.03% and operating margin of 15.85% are the cleaner read on core profitability. Gross margin has been remarkably stable in a 23.0–24.6% band over the last five quarters (23.37%, 23.06%, 23.01%, 24.62%, 24.12%), which is consistent with a diversified industrial/insurance mix where underwriting margins offset rail and manufacturing cost pressure; the Q2 2026 EBITDA margin of 20.72% versus 17.55% in Q4 2025 shows operating leverage is intact.
Balance-sheet strength is the defining feature: debt-to-equity is just 0.194, the current ratio is 6.75x, and interest coverage of roughly 13.1x (Q2 2026) leaves enormous cushion, while ROE of 9.33% and ROA of 6.01% are respectable for a capital-heavy conglomerate but below what the insurance and rail segments could earn in isolation. Free cash flow is substantial — $24.22 billion TTM, with quarterly FCF of $5.57 billion in Q2 2026, $5.45 billion in Q1 2026 and $4.99 billion in Q4 2025 — but capital expenditure is heavy at $5.65 billion in Q2 2026, and the company is simultaneously deploying capital into investments ($172.28 billion of purchases in Q2 2026 against $154.02 billion of maturities) and buybacks ($4.21 billion in Q2 2026). The FCF yield is low (roughly 2.2% on the $1.085 trillion market cap) and the price-to-free-cash-flow ratio of about 23.6x reflects that Berkshire's cash generation is reinvested rather than distributed — there is no dividend (payout ratio 0), so total return depends entirely on per-share intrinsic value compounding, which the fortress balance sheet and 0.19 debt-to-equity make highly durable but not high-yielding.
Quarterly Revenue
$101.8B
2026-06
Revenue YoY Growth
+10.0%
YoY Comparison
Gross Margin
23.4%
Latest Quarter
Free Cash Flow
$24.2B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BRK-B Overvalued?
Because net income is positive, the PE ratio is the appropriate primary metric, and the picture is nuanced: the trailing PE of 16.21x is modest for a quality compounder, but the forward PE of 25.45x is materially higher, implying the market expects earnings to normalize downward from the investment-gain-inflated trailing base — consensus 2027 EPS of about $22.91 versus the current run-rate suggests the trailing multiple flatters the stock. The price-to-book ratio of 1.51x is the more Berkshire-appropriate anchor, sitting close to the long-run 1.3–1.6x band, while the price-to-sales ratio of 2.92x and price-to-cash-flow of 23.61x are secondary cross-checks; the negative PEG ratio of -0.65 is not meaningful given the earnings distortion and should be disregarded. The gap between 16.2x trailing and 25.5x forward is the key valuation signal: it tells investors that the market is not pricing a growth acceleration but rather a reversion of investment gains, so upside must come from book value compounding and buybacks, not multiple expansion.
Against the Financial Services/Insurance-Diversified peer set, Berkshire screens cheap on book value but expensive on cash flow: a 1.51x P/B versus a sector that typically trades at 1.2–1.8x is roughly in line to modestly above the middle of the range, while the 16.2x trailing PE compares favorably with diversified insurers and financials often trading at 12–18x — implying no meaningful premium despite Berkshire's superior balance sheet, 18.03% net margin and 0.19 debt-to-equity. The 2.92x P/S is elevated relative to pure insurers (typically 1.0–1.5x) but reflects the consolidated industrial/retail revenue base, and the 23.61x P/CF is rich versus the sector's high-teens norm, largely because Berkshire's cash flow is consumed by capex and investment purchases. On balance, the stock trades at a modest discount to what its quality and earnings stability would justify versus peers, with the discount attributable to its size, lack of dividend, and the conglomerate structure that obscures segment-level value.
Historically, Berkshire's own valuation band has been wide: the quarterly P/B ratio has ranged from about 1.31x (Q3 2022) to 1.75x (Q1 2025), and the current 1.51x sits near the middle-to-upper portion of that range — not cheap, but far from the 1.75x peak. The trailing PE history is far noisier (from 4.2x in Q4 2021 to 62.4x in Q1 2025) because of investment gains and losses, which is precisely why book value is the better historical anchor; at 1.51x P/B versus a five-year average near 1.45x, the stock is trading at a roughly 4% premium to its own norm, consistent with the market pricing in steady but not heroic expectations. The read-through is that Berkshire is fairly valued to slightly rich on its own history — a value opportunity only if book value compounds at double digits and buybacks continue at the current $4.2 billion quarterly pace, and a source of downside risk if investment gains reverse and the forward PE of 25.45x proves to be the truer earnings multiple.
PE
16.2x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 4x~26x
vs. Industry Avg
14.2x
Industry PE ~14.2x*
EV/EBITDA
16.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on earnings quality rather than solvency. Q2 2026 net income of $25.67 billion was inflated by $14.57 billion of other income (mark-to-market gains), versus a -$3.06 billion other-income drag in Q1 2026 that cut net income to $10.11 billion — a swing that shows EPS is hostage to equity portfolio moves, not underwriting. The forward PE of 25.45x versus 16.21x trailing means the market already discounts a reversion of those gains, so any shortfall in core operating profit (Q2 operating margin 17.18%, Q1 16.41%) or a turn in the insurance pricing cycle would hit the multiple. Capital intensity is another constraint: Q2 2026 capex of $5.65 billion plus $172.28 billion of investment purchases consumed most of the $5.57 billion quarterly FCF, leaving the ~2.2% FCF yield dependent on continued asset sales and maturities ($154.02 billion in Q2). Revenue concentration in insurance ($26.18 billion) and manufacturing ($22.57 billion) means a soft underwriting market or industrial slowdown would bite the two largest segments simultaneously.
Market and competitive risks are dominated by valuation compression and the stock's own momentum. At 1.51x book versus a five-year average near 1.45x and a historical band of 1.31x–1.75x, BRK-B is priced for steady but not heroic compounding; a re-rating toward the 1.31x trough would imply roughly a 13% decline on book value alone. The 23.61x price-to-cash-flow versus the sector's high-teens norm and the 2.92x P/S versus pure insurers at 1.0–1.5x leave little room for disappointment, and the 25.45x forward PE is the number that matters if investment gains normalize. Beta of 0.571 cuts both ways: it cushions drawdowns but means the stock will lag in a sharp risk-on melt-up, and the recent 12.77% one-month gain against SPY's -4.99% reflects a defensive rotation that could reverse if market leadership shifts back to growth. Thin coverage (3 analysts, consensus "none") and a 2.67 short ratio mean price discovery is inefficient and the stock is more exposed to index flows and buyback cadence than to sell-side support.
The worst-case scenario is a chain of three events: investment gains reverse as equity markets fall, insurance underwriting margins normalize as the pricing cycle turns, and the stock de-rates from 1.51x toward its 1.31x historical trough. In that path, the forward PE of 25.45x becomes the operative multiple and the average target of $555.67 (already 2.7% below spot) gives way to the low target of $510.00, a 10.7% decline from $570.95. A fuller de-rating toward the 52-week low of $464.01 would represent roughly -18.7% from the current price, and the 52-week max drawdown of -14.95% shows that a mid-teens pullback is well within this stock's recent historical range. Realistically, an investor should underwrite a -11% to -19% downside in the adverse case ($510 to $464), with the $540–$542 October breakout zone as the first technical warning level.
FAQ
The most severe risk is earnings quality: Q2 2026 net income of $25.67 billion was inflated by $14.57 billion of mark-to-market other income, versus a -$3.06 billion drag in Q1 2026 that cut net income to $10.11 billion, so a market decline could swing EPS sharply and expose the 25.45x forward multiple. Second is insurance cycle risk — the $26.18 billion Insurance segment's underwriting margins could compress as pricing turns, hitting the largest profit engine alongside a potential industrial slowdown in the $22.57 billion Manufacturing segment. Third is valuation compression: at 1.51x book, a de-rating toward the 1.31x historical trough would imply roughly a 13% decline on book value alone, and the stock already trades above the $555.67 average analyst target. Fourth is macro and market-structure risk — beta of 0.571 cushions drawdowns but means the stock lags in risk-on rallies, and with only 3 analysts and a 2.67 short ratio, price discovery is thin and flows plus buyback cadence dominate. Ranked by severity: earnings-quality reversal first, insurance margin compression second, valuation de-rating third, and thin coverage/macro rotation last.
The 12-month outlook splits into three scenarios. The base case carries 50% probability with a $540–$575 range, assuming revenue growth moderates to 8–10% from the Q2 2026 pace of 10.04%, gross margin holds in the 23.0–24.6% band, buybacks continue near $4.2 billion per quarter, and investment gains normalize rather than reverse — the stock consolidates around the $555.67 average target. The bull case at 25% probability targets $600–$628, matching the high analyst target, and requires strong underwriting through the pricing cycle plus deployment of the ~$41.4 billion cash pile into a large acquisition or accelerated buybacks. The bear case at 25% probability targets $464–$510, aligning with the low analyst target of $510 and the 52-week low of $464.01, driven by equity market weakness reversing portfolio gains and a de-rating toward the 1.31x book trough. The base case is most likely, and its key assumption is that book value compounds steadily while the 25.45x forward PE caps upside until 2027 EPS of about $22.91 is delivered.
The valuation is mixed depending on the metric, but leans fairly valued to slightly rich on the company's own history. The trailing PE of 16.21x looks cheap for a quality compounder and compares favorably with diversified insurers trading at 12–18x, but the forward PE of 25.45x tells a different story — it implies the market expects earnings to normalize down from the investment-gain-inflated trailing base toward consensus 2027 EPS of about $22.91. The more Berkshire-appropriate anchor, price-to-book at 1.51x, sits near the middle of the historical 1.31x–1.75x band and roughly 4% above the five-year average of about 1.45x. Secondary metrics are less supportive: price-to-cash-flow of 23.61x is rich versus the sector's high-teens norm and the FCF yield is only about 2.2%. The market is paying a modest premium to history for steady book-value compounding, not a discount — upside requires double-digit book growth and continued $4.2 billion quarterly buybacks rather than multiple expansion.
From a risk/reward standpoint the answer is conditional. The quality case is strong: 10.04% YoY revenue growth to $101.81 billion, a 0.194 debt-to-equity ratio, $24.22 billion of TTM free cash flow, and a beta of 0.571 that delivered 15.76% one-year returns against SPY's 9.59%. But the entry price is the problem — at $570.95 the stock trades 2.7% above the $555.67 average analyst target, with the low target of $510.00 implying 10.7% downside, and it sits at 87.5% of its 52-week range after a 12.77% one-month surge. The biggest downside risk is a reversal of the investment gains that produced Q2 2026's $25.67 billion net income, which would expose the 25.45x forward PE as the operative multiple. It is a good buy for long-horizon investors seeking low-volatility quality exposure, particularly on a pullback into the $510–$540 zone; it is a poor buy for anyone chasing the recent momentum at current levels.
BRK-B is structurally a long-term holding, not a trading vehicle. It pays no dividend (payout ratio 0%), so total return depends entirely on per-share intrinsic value compounding through retained earnings, buybacks and capital deployment — a process measured in years, not quarters. Its beta of 0.571 and 52-week max drawdown of only -14.95% mean it lacks the volatility that short-term traders need, and the 2.67 short ratio with 5.35 million average volume indicates no squeeze or event-driven dynamics to exploit. Earnings visibility is clouded quarter-to-quarter by mark-to-market swings (Q2 2026 EPS of $11.91 versus Q1 2026's $4.68), which makes short-term earnings-based trading unreliable. A minimum holding period of three to five years is appropriate, allowing at least one full insurance pricing cycle and a complete investment-gain cycle to play out; short-term traders should look elsewhere, and even long-term buyers should consider staging entries given the stock sits 2.6% below its 52-week high and above the average analyst target.